2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $9.00.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 2seventy bio in a research note on Saturday.

2seventy bio Stock Performance

Shares of NASDAQ TSVT traded up $0.17 during mid-day trading on Friday, reaching $2.61. The company’s stock had a trading volume of 380,020 shares, compared to its average volume of 398,038. 2seventy bio has a 1-year low of $2.35 and a 1-year high of $6.40. The stock has a market capitalization of $134.65 million, a P/E ratio of -1.40 and a beta of 1.76. The stock has a 50-day moving average of $3.28 and a two-hundred day moving average of $4.15.

Institutional Investors Weigh In On 2seventy bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Erste Asset Management GmbH acquired a new position in shares of 2seventy bio in the third quarter valued at approximately $25,000. SkyView Investment Advisors LLC increased its stake in 2seventy bio by 25.0% in the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after buying an additional 2,500 shares during the period. Readystate Asset Management LP purchased a new position in 2seventy bio during the 3rd quarter worth $53,000. GSA Capital Partners LLP purchased a new position in 2seventy bio during the 3rd quarter worth $64,000. Finally, Intech Investment Management LLC acquired a new stake in shares of 2seventy bio in the 3rd quarter worth $69,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.